Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B10 | O60218 | 4/20 | 0.49 |
| ▸ | AKR1B1 | P15121 | 4/20 | 0.49 |
| ▸ | CA12 | O43570 | 6/20 | 0.48 |
| ▸ | CA7 | P43166 | 6/20 | 0.48 |
| ▸ | CA9 | Q16790 | 6/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 6/20 | 0.48 |
| ▸ | CA1 | P00915 | 5/20 | 0.48 |
| ▸ | MET | P08581 | 4/20 | 0.48 |
| ▸ | CA4 | P22748 | 3/20 | 0.48 |
| ▸ | CA6 | P23280 | 3/20 | 0.48 |
| ▸ | CA5A | P35218 | 3/20 | 0.48 |
| ▸ | CA5B | Q9Y2D0 | 3/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 3/20 | 0.45 |
| ▸ | ESR1 | P03372 | 4/20 | 0.42 |
| ▸ | APP | P05067 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | TYR | P14679 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13242601 | 0.97 | AKR1B10 (0.48) | AKR1B10AKR1B1CA12CA7CA9 | |
| SCHEMBL13242592 | 0.93 | CA12 (0.50) | AKR1B10AKR1B1CA12CA7CA9 | |
| SCHEMBL13242597 | 0.88 | CA12 (0.50) | AKR1B10AKR1B1CA12CA7CA9 | |
| SCHEMBL13242538 | 0.84 | MET (0.57) | CA12CA7CA9CA14CA1 | |
| SCHEMBL13242593 | 0.82 | AKR1B10 (0.59) | AKR1B10AKR1B1CA12CA7CA9 | |
| SCHEMBL13242595 | 0.82 | AKR1B10 (0.59) | AKR1B10AKR1B1CA12CA7CA9 | |
| SCHEMBL13242542 | 0.81 | MET (0.56) | CA12CA7CA9CA14CA1 | |
| SCHEMBL13242617 | 0.81 | AKR1B10 (0.57) | AKR1B10AKR1B1CA12CA7CA9 | |
| SCHEMBL13242587 | 0.81 | AKR1B10 (0.57) | AKR1B10AKR1B1CA12CA7CA9 | |
| SCHEMBL13242588 | 0.80 | CA12 (0.65) | AKR1B10AKR1B1CA12CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100179192-A1 | USE OF NITRIC OXIDE RELEASING COMPOUNDS IN THE TREATMENT OF CHRONIC PAIN | NICOX S.A. (FR) | 2010-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179192-A1 | USE OF NITRIC OXIDE RELEASING COMPOUNDS IN THE TREATMENT OF CHRONIC PAIN | NOS1, NOS2, NOS3 | AKR1B10 414/4885AKR1B1 236/4885CA12 3464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.